Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2008

01-06-2008 | Epidemiology

Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors

Authors: Marilyn L. Kwan, Laurel A. Habel, E. Dawn Flick, Charles P. Quesenberry, Bette Caan

Published in: Breast Cancer Research and Treatment | Issue 3/2008

Login to get access

Abstract

Purpose

We examined the association between post-diagnosis statin use (3-hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] inhibitors) and risk of breast cancer recurrence.

Materials and methods

The study included 1945 early stage breast cancer survivors participating in the Life After Cancer Epidemiology (LACE) Study. Women who were diagnosed from 1997 to 2000 and identified from the Kaiser Permanente Northern California (KPNC) Cancer Registry entered the cohort on average 2 years post-diagnosis. Information on statin use was obtained from the KPNC pharmacy database. A total of 210 breast cancer recurrences were reported and verified by medical record review. Cox proportional hazard models were used to estimate rate ratios (RR) and 95% confidence intervals (CI).

Results

The mean duration of statin use in the cohort among those who initiated use post-diagnosis was 1.96 years, and lipophilic statins were mainly used (97.8%). Starting statins after diagnosis was suggestive of a decreased risk of breast cancer recurrence (RR = 0.67; 95% CI: 0.39–1.13). Risk of recurrence decreased with increasing duration of statin use after diagnosis (p linear trend = 0.02).

Conclusion

Our findings provide initial support for an inverse association between post-diagnosis, lipophilic statin use and risk of breast cancer recurrence.
Literature
1.
Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278PubMedCrossRef
2.
Campbell MJ, Esserman LJ, Zhou Y et al (2006) Breast cancer growth prevention by statins. Cancer Res 66(17):8707–8714PubMedCrossRef
3.
Beck P, Wysowski DK, Downey W, Butler-Jones D (2003) Statin use and the risk of breast cancer. J Clin Epidemiol 56(3):280–285PubMedCrossRef
4.
Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR (2004) The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 100(11):2308–2316PubMedCrossRef
5.
Cauley JA, McTiernan A, Rodabough RJ et al (2006) Statin use and breast cancer: prospective results from the Womens Health Initiative. J Natl Cancer Inst 98(10):700–707PubMedCrossRef
6.
Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S (2002) Statin use and the risk of breast and prostate cancer. Epidemiology 13(3):262–267PubMedCrossRef
7.
Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE (2005) Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 165(19):2264–2271PubMedCrossRef
8.
Friis S, Poulsen AH, Johnsen SP et al (2005) Cancer risk among statin users: a population-based cohort study. Int J Cancer 114(4):643–647PubMedCrossRef
9.
Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ (2004) The risk of cancer in users of statins. J Clin Oncol 22(12):2388–2394PubMedCrossRef
10.
Kaye JA, Jick H (2004) Statin use and cancer risk in the general practice research database. Br J Cancer 90(3):635–637PubMedCrossRef
11.
Caan B, Sternfeld B, Gunderson E, Coates A, Quesenberry C, Slattery ML (2005) Life after cancer epidemiology (LACE) study: a cohort of early stage breast cancer survivors (United States). Cancer Causes Control 16(5):545–556PubMedCrossRef
12.
Allison PD (1995) Survival analysis using SAS: a practical guide. SAS Press, Cary, NC
13.
Hosmer DW, Lemeshow S (1999) Applied survival analysis: regression modeling of time to event data. Wiley, New York
14.
Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5(12):930–942PubMedCrossRef
15.
Katz MS (2005) Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol 2(2):82–89PubMedCrossRef
16.
Duncan RE, El-Sohemy A, Archer MC (2005) Statins and cancer development. Cancer Epidemiol Biomarkers Prev 14(8):1897–1898PubMedCrossRef
17.
Esserman L, Campbell M, Shoemaker M, Lobo M, Marx C, Benz C (2004) Breast cancer inhibition by statins. J Clin Oncol 22(97s):(Suppl; abstr 1003)
18.
Mueck AO, Seeger H, Wallwiener D (2003) Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause 10(4):332–336PubMedCrossRef
19.
Seeger H, Wallwiener D, Mueck AO (2003) Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes 111(1):47–48PubMedCrossRef
20.
Kumar AS, Campbell M, Benz CC, Esserman LJ (2006) A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes. J Clin Oncol 24(13):2127; author reply 2127–2128
21.
Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS, Gomez DE (1998) Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50(1):83–93PubMedCrossRef
22.
Farina HG, Bublik DR, Alonso DF, Gomez DE (2002) Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin Exp Metastasis 19(6):551–559PubMedCrossRef
23.
Bonovas S, Filioussi K, Tsavaris N, Sitaras NM (2005) Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23(34):8606–8612PubMedCrossRef
24.
Kochhar R, Khurana V, Bejjanki H, Caldito G, Fort C (2005) Statins to reduce breast cancer risk: A case control study in US female veterans. J Clin Oncol 23(7s):(Suppl; abstr 514)
25.
Mortimer J, Axelrod R, Zimbro K (2004) Effect of statins on breast cancer incidence: findings from the Sentara Health Plan. Proc Am Soc Clin Oncol 22(93):(abstr 373)
26.
Selby JV, Smith DH, Johnson ES, Raebel MA, Friedman GD, McFarland BH (2005) Kaiser permanente medical care program. In: BL S (ed) Pharmacoepidemiology. Wiley, West Sussex, pp 241–259
27.
Setoguchi S, Avorn J, Schneeweiss S (2005) Statins and the risk of colorectal cancer. N Engl J Med 353(9):952–954; author reply 952–954
28.
Metadata
Title
Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors
Authors
Marilyn L. Kwan
Laurel A. Habel
E. Dawn Flick
Charles P. Quesenberry
Bette Caan
Publication date
01-06-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9683-8

Other articles of this Issue 3/2008

Breast Cancer Research and Treatment 3/2008 Go to the issue

Clinical Trial

Sentinel node biopsy in patients with multiple breast cancer

Epidemiology

The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data

Clinical Trial

Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen

Preclinical Study

Indole-3-carbinol-induced modulation of NF-κB signalling is breast cancer cell-specific and does not correlate with cell death

Clinical Trial

BRCA1/2 mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy

Preclinical Study

Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits